J. Goldman & CO LP Bellus Health Inc. Transaction History

J. Goldman & CO LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.14 - $8.53 $939,445 - $1.12 Million	-131,575 Reduced 70.9%	54,000 $388,000
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $877,213 - $1.15 Million	106,717 Added 135.33%	185,575 $1.53 Million
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $302,975 - $406,224	33,852 Added 75.22%	78,858 $833,000
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $448,608 - $695,828	-69,444 Reduced 60.68%	45,006 $416,000
Q1 2022 May 16, 2022	SELL	$5.56 - $7.99 $474,579 - $681,994	-85,356 Reduced 42.72%	114,450 $787,000
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $1.05 Million - $1.66 Million	199,806 New	199,806 $1.61 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.